Extracellular adenosine is increased by which of the following DMARDs?
**Core Concept**
Adenosine is a purine nucleoside that plays a crucial role in various physiological processes, including energy metabolism, neurotransmission, and vasodilation. Increased extracellular adenosine levels can lead to vasodilation, anti-inflammatory effects, and immune suppression, which are beneficial in treating certain autoimmune diseases.
**Why the Correct Answer is Right**
Minocycline, a second-generation tetracycline derivative, is used as a DMARD (Disease-Modifying Antirheumatic Drug) in the treatment of rheumatoid arthritis. Minocycline increases extracellular adenosine levels by inhibiting the enzyme CD73, also known as ecto-5'-nucleotidase, which is responsible for converting AMP to adenosine. This increase in adenosine leads to its anti-inflammatory and immunosuppressive effects, contributing to the therapeutic efficacy of minocycline in treating autoimmune diseases.
**Why Each Wrong Option is Incorrect**
**Option A:** Sulfasalazine does not directly increase extracellular adenosine levels. It is a DMARD that works by inhibiting the synthesis of pro-inflammatory cytokines and inducing the production of anti-inflammatory cytokines.
**Option B:** Leflunomide is a DMARD that inhibits the enzyme dihydroorotate dehydrogenase, which is involved in pyrimidine synthesis. It does not directly affect adenosine levels.
**Option C:** Methotrexate is a DMARD that works by inhibiting dihydrofolate reductase and interfering with DNA synthesis. It does not directly increase extracellular adenosine levels.
**Clinical Pearl / High-Yield Fact**
Minocycline's unique mechanism of increasing extracellular adenosine levels makes it a valuable addition to the treatment of autoimmune diseases, such as rheumatoid arthritis. Its anti-inflammatory and immunosuppressive effects are particularly beneficial in reducing disease activity and improving patient outcomes.
**Correct Answer:** C. Minocycline.